Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands

X
Trial Profile

Observational Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms REWARD
  • Sponsors Amgen; Celgene Corporation
  • Most Recent Events

    • 13 Jul 2022 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2022 Interim results ( as of 16 September 2021; n=98) assessing patients with psoriatic arthritis who received apremilast for 12 months, presented at the 23rd Annual Congress of the European League Against Rheumatism.
    • 05 Jun 2021 Interim results (n=85; data cutoff date: 3 Nov 2020) presented at the 22nd Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top